drugset / Trial / NCT05252338
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVSQIV in Healthy Adults
Non-randomizedSequentialOpen-labelPrevention
Summary
This study aims to evaluate the safety and reactogenicity profile of CVSQIV at different dose levels.
Timeline
- Start
- 2022-02-07
- Primary completion
- 2022-09-27
- Completion
- 2022-09-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CVSQIV | Messenger RNA (mRNA) | 3 ug | Intramuscular |
| Subject | CVSQIV | Messenger RNA (mRNA) | 6 ug | Intramuscular |
| Subject | CVSQIV | Messenger RNA (mRNA) | 12 ug | Intramuscular |
| Subject | CVSQIV | Messenger RNA (mRNA) | 20 ug | Intramuscular |
| Subject | CVSQIV | Messenger RNA (mRNA) | 28 ug | Intramuscular |